403 related articles for article (PubMed ID: 26827795)
21. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
[TBL] [Abstract][Full Text] [Related]
22. Dysregulation of miR-122, miR-574 and miR-375 in Egyptian patients with breast cancer.
Elghoroury EA; Abdelghafar EE; Kamel S; Awadallah E; Shalaby A; El-Saeed GSM; Mahmoud E; Kamel MM; Abobakr A; Yousef RN
PLoS One; 2024; 19(5):e0298536. PubMed ID: 38820252
[TBL] [Abstract][Full Text] [Related]
23. A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: An integrated study of 1,110 cases.
Xiong DD; Lv J; Wei KL; Feng ZB; Chen JT; Liu KC; Chen G; Luo DZ
Oncol Rep; 2017 Jun; 37(6):3297-3304. PubMed ID: 28440475
[TBL] [Abstract][Full Text] [Related]
24. Identification of microRNAs in Nipple Discharge as Potential Diagnostic Biomarkers for Breast Cancer.
Zhang K; Zhao S; Wang Q; Yang HS; Zhu J; Ma R
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S536-44. PubMed ID: 25976861
[TBL] [Abstract][Full Text] [Related]
25. Identification of circulating microRNA signatures for breast cancer detection.
Chan M; Liaw CS; Ji SM; Tan HH; Wong CY; Thike AA; Tan PH; Ho GH; Lee AS
Clin Cancer Res; 2013 Aug; 19(16):4477-87. PubMed ID: 23797906
[TBL] [Abstract][Full Text] [Related]
26. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls.
Hu Z; Dong J; Wang LE; Ma H; Liu J; Zhao Y; Tang J; Chen X; Dai J; Wei Q; Zhang C; Shen H
Carcinogenesis; 2012 Apr; 33(4):828-34. PubMed ID: 22298638
[TBL] [Abstract][Full Text] [Related]
27. The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study.
Elshafei A; Shaker O; Abd El-Motaal O; Salman T
Tumour Biol; 2017 Jun; 39(6):1010428317705765. PubMed ID: 28618945
[TBL] [Abstract][Full Text] [Related]
28. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
29. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
30. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer.
Jiang X; Du L; Wang L; Li J; Liu Y; Zheng G; Qu A; Zhang X; Pan H; Yang Y; Wang C
Int J Cancer; 2015 Feb; 136(4):854-62. PubMed ID: 24961907
[TBL] [Abstract][Full Text] [Related]
31. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas.
Yang C; Wang C; Chen X; Chen S; Zhang Y; Zhi F; Wang J; Li L; Zhou X; Li N; Pan H; Zhang J; Zen K; Zhang CY; Zhang C
Int J Cancer; 2013 Jan; 132(1):116-27. PubMed ID: 22674182
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers.
van Schooneveld E; Wouters MC; Van der Auwera I; Peeters DJ; Wildiers H; Van Dam PA; Vergote I; Vermeulen PB; Dirix LY; Van Laere SJ
Breast Cancer Res; 2012 Feb; 14(1):R34. PubMed ID: 22353773
[TBL] [Abstract][Full Text] [Related]
33. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection.
Schrauder MG; Strick R; Schulz-Wendtland R; Strissel PL; Kahmann L; Loehberg CR; Lux MP; Jud SM; Hartmann A; Hein A; Bayer CM; Bani MR; Richter S; Adamietz BR; Wenkel E; Rauh C; Beckmann MW; Fasching PA
PLoS One; 2012; 7(1):e29770. PubMed ID: 22242178
[TBL] [Abstract][Full Text] [Related]
34. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer.
Hua Y; Chen H; Wang L; Wang F; Wang P; Ning Z; Li Y; Liu L; Chen Z; Meng Z
Cancer Biomark; 2017 Jul; 20(1):95-100. PubMed ID: 28759959
[TBL] [Abstract][Full Text] [Related]
35. U6 is not a suitable endogenous control for the quantification of circulating microRNAs.
Xiang M; Zeng Y; Yang R; Xu H; Chen Z; Zhong J; Xie H; Xu Y; Zeng X
Biochem Biophys Res Commun; 2014 Nov; 454(1):210-4. PubMed ID: 25450382
[TBL] [Abstract][Full Text] [Related]
36. Breast tissue-based microRNA panel highlights microRNA-23a and selected target genes as putative biomarkers for breast cancer.
Eissa S; Matboli M; Shehata HH
Transl Res; 2015 Mar; 165(3):417-27. PubMed ID: 25445205
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer.
Yang L; Feng Y; Qi P; Xu S; Zhou Y
J Biol Regul Homeost Agents; 2016; 30(4):1041-1045. PubMed ID: 28078851
[TBL] [Abstract][Full Text] [Related]
38. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
39. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer.
Si H; Sun X; Chen Y; Cao Y; Chen S; Wang H; Hu C
J Cancer Res Clin Oncol; 2013 Feb; 139(2):223-9. PubMed ID: 23052693
[TBL] [Abstract][Full Text] [Related]
40. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer.
Zhao FL; Hu GD; Wang XF; Zhang XH; Zhang YK; Yu ZS
J Int Med Res; 2012; 40(3):859-66. PubMed ID: 22906258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
